CULVER CITY, Calif. --(BUSINESS WIRE)--Feb. 13, 2018-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, today announced that
First Combination Off The Shelf NK And Adaptive Immunotherapy Trial To Be Initiated For Pancreatic, Lung, Breast, Colon, Melanoma, Sarcoma, Chordoma, Head And Neck, Non Hodgkin’s Lymphoma, Merkel Cell And Ovarian Cancers. First Whole Genome, Transcriptomic, Proteomic (GPS Cancer) Informed
Announces a Record 25 Letters of Authorization to Proceed with Clinical Trials Covering 12 Novel Biological Molecules in 20 Tumor Types January 5, 2018 — Culver City, California — NantWorks , the parent organization of NantHealth (NASDAQ: NH) and NantKwest (NASDAQ: NK) announced today that Dr.
CULVER CITY, Calif. – March 22, 2016 – Cancer Moonshot 2020 , the nation's most comprehensive cancer collaborative initiative formed to accelerate next-generation immunotherapy in cancer, announced today the selection of Schulman IRB as its national institutional review board (IRB) of record.
La Jolla, CA – February 24, 2016 –Patrick Soon-Shiong, M.D., founder and CEO of NantWorks , LLC, and leader of the Cancer MoonShot 2020 program, will deliver the keynote session, “Cancer Moonshot 2020 & The National Immunotherapy Coalition,” at the sixth annual Biocom Global Life Science
Soon-Shiong taps biotech hub for talent, biomedical manufacturing prowess By Bradley J. Fikes (/staff/bradley-fikes/) | 3:33 p.m. March 3, 2016 If physician turned billionaire biotech entrepreneur Dr. Patrick Soon-Shiong succeeds in his ambitious goal to defeat cancer by 2020, San Diego County's
San Diego and Cardiff-by-the-Sea, CA (Dec. 19, 2014) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, and Conkwest, Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ® , a Natural